After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Organogenesis Holdings Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Organogenesis Holdings Inc is $824.93M. A total of 2.25 million shares were traded on the day, compared to an average of 1.32M shares.
In the most recent transaction, NUSSDORF GLENN H bought 251,001 shares of ORGO for 3.09 per share on May 14 ’25. After the transaction, the Director now owns 251,001 company shares. In a previous transaction on May 15 ’25, NUSSDORF GLENN H bought 107,494 shares at 2.99 per share. ORGO shares that Director owns now total 358,495.
Among the insiders who sold shares, NUSSDORF GLENN H disposed of 18,620 shares on Jun 10 ’25 at a per-share price of $3.56. This resulted in the Director holding 335,719 shares of ORGO after the transaction. In another insider transaction, NUSSDORF GLENN H sold 4,156 shares at $3.50 per share on Jun 09 ’25. Company shares held by the Director now total 354,339.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ORGO has a high of $6.71 and a low of $2.61.
As of this writing, ORGO has an earnings estimate of $0.21 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of $0.21 per share and a lower estimate of $0.21. The company reported an EPS of $0.07 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ORGO’s latest balance sheet shows that the firm has $113.93M in Cash & Short Term Investments as of fiscal 2021. There were $132.30M in debt and $82.70M in liabilities at the time. Its Book Value Per Share was $2.01, while its Total Shareholder’s Equity was $241.34M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ORGO is Buy with a score of 4.33.
